Viking Therapeutics (VKTX) is positioning itself in a competitive obesity drug market, currently dominated by heavyweights like Eli Lilly and Novo Nordisk. Their main candidate, VK2735, has demonstrated promising weight loss results in mid-stage trials, but future success is highly uncertain.
Market Potential
The weight loss drug market could reach approximately $95 billion by 2030, with broader GLP-1 medicines estimated near $200 billion. If VK2735 captures just 1% of this market, it could achieve $1.5 billion in annual sales, potentially increasing its valuation to $15 billion.
Investment Scenarios
- Best-case scenario: If VK2735 performs well and secures a 1% market share, a $1,000 investment might grow to $3,400.
- Higher expectations: To turn a $1,000 investment into $10,000, VK2735 would need to capture about 3% to 5% of the market and face minimal share dilution.
- Dilution factor: With rapid cash burn (around $603 million left), new share issues could dilute earnings. If shares increase by 33%, the investment value could drop to $2,500.
Competitive Landscape
Viking faces strong competition from established drugs such as tirzepatide and semaglutide, both offering extensive market presence and efficacy. The arrival of VK2735 in 2028-2029 means it will enter a market with entrenched players.
Risks and Considerations
- Efficacy must be proven in larger trials.
- Potential stock drop of 60% to 80% if it fails to secure regulatory approval, possibly reducing a $1,000 investment to a few hundred dollars.
Conclusion
Investing in Viking Therapeutics is high-risk with uncertain rewards. While the best-case outlook is appealing, those considering it should weigh the high likelihood of variable outcomes and should treat it as a smaller position within a diversified portfolio.
